Trial Profile

Single Ascending Dose Tolerability Study of DG3173

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veldoreotide (Primary)
Indications Acromegaly; Carcinoid tumour; Diabetic retinopathy
Focus Adverse reactions
Sponsors Aspireo Pharmaceuticals

Most Recent Events

26 Feb 2009 Results reported in a DeveloGen media release.
17 Oct 2008 New trial record.
10 Oct 2008 Final results were expected in November 2008 according to a DeveloGen media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com